STOK
Stoke Therapeutics Inc (STOK)
Healthcare • NASDAQ • $32.89+0.30%
- Symbol
- STOK
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $32.89
- Daily Change
- +0.30%
- Market Cap
- $2.05B
- Trailing P/E
- N/A
- Forward P/E
- -10.52
- 52W High
- $40.22
- 52W Low
- $8.70
- Analyst Target
- $45.10
- Dividend Yield
- N/A
- Beta
- N/A
Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in Phase 1 clinical trials for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine for the treatment of Dravet syndrome is being evaluated in phase 3 clinical trials. The company also develops programs focused on various targets, including haploinsufficiency diseases of the central nervous system and eye. It has a license and collaboration with Biogen Inc. for the deve…
Company websiteResearch STOK on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.